Cameron Santoro is an associate editor for The American Journal of Managed Care® (AJMC®), AJMC.com, and The Center for Biosimilars®.
Tofacitinib Effective for AA, Earlier Intervention Improves Outcomes
March 20th 2024Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment plans for patients.
Read More
Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients With Moderate to Severe AA
March 14th 2024Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.
Read More
Night Light Pollution Linked to Breast Cancer, Particularly for Asian Populations, ER+ Cases
March 14th 2024A large-scale study suggests increased light at night exposure is linked to a higher risk of breast cancer, particularly in Asian populations and women with estrogen receptor-positive tumors (ER+).
Read More
Stable Treatment Remained in Early Breast Cancer Diagnosis During Pandemic
March 6th 2024A study of patients diagnosed with early breast cancer during the COVID-19 pandemic found that the public health crisis did not produce significant changes in or delays treatment, despite many women presenting with palpable tumors.
Read More
Experts Measure AA Severity With Key Factors, Reach Consensus on Treatment Decisions
February 29th 2024An expert survey using the eDelphi method pinpointed disease duration, treatment response, and mental health as crucial factors in a new multidimensional tool known as Alopecia Areata Severity and Morbidity Index (ASAMI), underlining the importance of personalized treatments for future research incorporating patient perspectives.
Read More
Multigene Assays Advance Genetic Testing in Breast Cancer, Drive Personalized Medicine
February 29th 2024Multigene assays allow for patients to receive personalized breast cancer treatment by identifying promising therapeutic targets, which could improve patient clinical outcomes in the long term and help providers better understand tumor biology.
Read More
Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL
February 20th 2024A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).
Read More
Swedish Study Links False-Positive Mammograms to Elevated Breast Cancer Risk
February 16th 2024Swedish women with prior false-positive mammograms, particularly those aged 60 to 75 with prior biopsies and low density, show elevated breast cancer risk, necessitating closer monitoring and better screening.
Read More
Cultural Influences, Surgical Decision-Making Approaches for Non-Caucasian Women With Breast Cancer
February 14th 2024Non-Caucasian patients with breast cancer face common influences in surgical decision-making due to fear, misinformation, cultural factors, and power dynamics, highlighting the need for patient-centered surgical decision-making.
Read More
Study Finds AA Associated With Connective Tissue, Ocular Diseases and Vitamin D Deficiency
February 9th 2024Meta-analysis results identify high and low associations of various comorbidities like vitamin D deficiencies, ocular diseases, among others in patients with alopecia areata (AA), to promptly manage and improve treatment outcomes.
Read More
Study Finds Significant Hair Regrowth in Patients With Patchy AA Following Baricitinib Treatment
February 7th 2024Baricitinib was found to be an effective treatment for patchy alopecia areata (AA), in a retrospective study, with most patients experiencing hair regrowth after 4 to 16 weeks of treatment.
Read More
Tofacitinib as AA Treatment Has High Drug Survival Rates, Manageable Side Effects
January 25th 2024A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.
Read More
Topical Corticosteroids: The Preferred First-Line Treatment for Pediatric Alopecia Areata
January 20th 2024A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia areata, regardless of age or hair loss severity.
Read More
Evaluating Hair Camouflage as a Tool for Black Women With Alopecia: A Critical Review
January 18th 2024Black women with alopecia often struggle between concealing their hair loss and protecting their fragile scalps, all while seeking to express their cultural identity and build self-confidence.
Read More
Dr Beau Raymond Shares Expertise on Public Health, Population Well-Being
January 12th 2024Sidney (Beau) Raymond, MD, MMM, FACP, chief medical officer of Ochsner Health Network, believes that the health care system should focus on preventing illness and disease, rather than just treating them after they occur.
Read More